Procollagen Type III N-terminal peptide (PIIINP) is a marker of collagen type III synthesis. It is used to assess fibrotic processes, especially in the liver and lungs.
Prokollagen Typ III im Serum should not be read as an isolated number only. This short overview summarizes when the marker matters, which questions it does not answer on its own, and what broader context makes the result more useful.
Prokollagen Typ III im Serum is most useful when it is interpreted together with the symptom pattern, the relevant category context, and the broader diagnostic question behind the test.
Prokollagen Typ III im Serum does not replace symptom timing, functional assessment, or the wider clinical picture. A marker may be informative without being the whole answer.
The next useful step is usually to connect Prokollagen Typ III im Serum to related markers, symptoms, and the broader context of the test rather than reading it as an isolated endpoint.
Procollagen Type III N-terminal peptide (PIIINP) is a fragment released during the production of type III collagen, a key structural protein in connective tissues such as skin, blood vessels, and internal organs. When the body synthesizes new collagen III, PIIINP enters the bloodstream, making it a useful indicator of ongoing collagen formation.
Measuring PIIINP in serum is primarily used to evaluate the degree of fibrosis (scarring) in conditions like liver fibrosis (often from chronic hepatitis or fatty liver), pulmonary fibrosis, and certain connective tissue diseases. While it does not replace imaging or biopsy, it can help monitor disease progression or treatment response.
PIIINP levels below the reference range (typically <10 µg/L or <10 ng/mL, lab-dependent) are considered normal. This test is primarily used to detect increased collagen production, so a low value is not clinically significant. Whether your result is 5 or 8 µg/L, both are within the normal range and do not indicate disease.
Elevated PIIINP levels suggest increased collagen synthesis, which can indicate active fibrosis in organs such as the liver or lungs. In chronic liver diseases (e.g., hepatitis B/C, alcoholic liver disease, non-alcoholic fatty liver disease), rising levels may reflect progression to fibrosis or cirrhosis. It can also be elevated in pulmonary fibrosis, systemic sclerosis, and some cancers.
The degree of elevation often correlates with the extent of fibrosis, but results should be interpreted alongside other tests and clinical findings. Values above 10 µg/L (10 ng/mL) are generally considered elevated, but exact thresholds are lab-dependent.
This result is not specific for ME/CFS or Long COVID. Read it together with the clinical question, symptoms, related findings and the laboratory reference range rather than in isolation.
Practical details are separated from the general FAQ so they are easier to find.
Prokollagen Typ III im Serum is most useful when it is interpreted together with the symptom pattern, the relevant category context, and the broader diagnostic question behind the test.
The next useful step is usually to connect Prokollagen Typ III im Serum to related markers, symptoms, and the broader context of the test rather than reading it as an isolated endpoint.
You now know which questions can matter when reading this result. With Elara you can keep the value and its surrounding context together over time.
Save the lab value with its date so individual measurements do not get lost.
See previous measurements together instead of relying on a single snapshot.
View Procollagen Type III N-Terminal Peptide (PIIINP) alongside symptom, energy, sleep and PEM entries without assuming one caused the other.
Export your history as a PDF — structured for the next check-up.
A high PIIINP level indicates increased production of type III collagen, often due to fibrosis (scarring) in organs like the liver or lungs. It is used as a non-invasive marker to monitor fibrotic diseases. However, a single elevated result does not diagnose a specific condition and requires further evaluation.
The most common conditions are liver fibrosis from chronic viral hepatitis, alcohol-related liver disease, and non-alcoholic steatohepatitis (NASH). It may also rise in lung fibrosis (idiopathic pulmonary fibrosis), systemic sclerosis, and some cancers. In liver disease, it can help assess the severity of fibrosis without a biopsy.
No, PIIINP is not organ-specific; it reflects systemic collagen III synthesis. While it is often used in liver contexts, it can be elevated in fibrosis of any organ. Therefore, results must be correlated with the patient's clinical picture and other diagnostic tests.
Prokollagen Typ III im Serum does not replace symptom timing, functional assessment, or the wider clinical picture. A marker may be informative without being the whole answer.
This biomarker gains value when it is connected to symptom patterns, daily function, and structured self-observation instead of being read in isolation.
Reduced capacity, multisystem symptoms, and delayed worsening often make more sense when the broader ME/CFS pattern is considered.
Markers linked to sleep, stress, recovery, hormones, or metabolism often become more useful when viewed through pacing and daily load management.
Questionnaires help connect biomarkers to symptom patterns, functional limits, and patient-reported change over time.
Markers from the same system can add useful context when a single lab value is hard to interpret on its own.
No individual medical review is documented.
This English content was created with AI assistance and automatically validated. This is not an individual medical review.
This information does not replace medical advice. Lab values should be assessed in the context of your medical history, the reason for testing and other findings. Elara provides health information for orientation — not diagnoses or treatment decisions.
Bring your lab values, symptoms and energy into one shared context — so you walk into your next appointment more informed and structured.
